7/23/2019 A1 Strategic Memo Final

1/13

S

U

7/23/2019 A1 Strategic Memo Final

2/13

CONTENTS

INTRODUCTION...........................................................................................................................1

ACQUISITION AND JOINT VENTURES....................................................................................2

SWOT ANALYSIS..........................................................................................................................3

FRED DAVID TOW MATRIX....................................................................................................4

DIVERSIFIED REVENUE BASE..................................................................................................5

FINANCIAL ANALYSIS OF MERGED ENTITY........................................................................5

SUN PHARMATACTICS AND STRATEGY...............................................................................!

LEADERSHIP TEAM....................................................................................................................."

DIAMOND STRATEGY APPLIED TO SUN PHARMA..............................................................#QSPM TOOL FOR DECISION MA$ING.....................................................................................#

TARNISHED BRAND IMAGE ISSUE OF RANBAXY...............................................................%

FUTURE STRATEGY& REMEDIAL ACTIONS..........................................................................1'

REFERENCES..............................................................................................................................1'

7/23/2019 A1 Strategic Memo Final

3/13

ABSTRACT

T()* +,-+/ -+0),* /(, ,/), *)* 67/ 897)*)/) : R6; 6 S7 P(+)8 :)/ ) S7 P(+

7/23/2019 A1 Strategic Memo Final

4/13

INTRODUCTIONS7 P(+,,+)8+=)> / C +=/( +)0,+*. S,0,+ :8/+* )?, ,8+=/( ,+-()88(>,* /+*)/) ) 8)/ >+=/( ) /(, -(+)> 1

7/23/2019 A1 Strategic Memo Final

5/13

ACQUISITION AND JOINT VENTURES

S7 P(+

7/23/2019 A1 Strategic Memo Final

6/13

STRENGTHS

KD., +.=/( -./,4/)23 )4 I41)2

THREATS

KS/+)4>,4/G.0,+4732/).4*

KP+.178/L)26)3)/5C32)/(* / /?,0/>, : --+/7)/),*1. U*, */+> )*/+)67/)

,/=+? :+ *,* ) ,)>>+=/( -/,/).

Opportunity-Weaness (OW)

Strategies

O0,+8 0/>, :--+/7)/),*

1. U*, 6+ -+/:) /+,** ,:,8/*.2. P/,/ -+78/* ) ,)>,/ G0,+7/)*

2. P+78/ L)6))/ C) )*/+)67/) /0,+8*.

7/23/2019 A1 Strategic Memo Final

7/13

DIVERSIFIED REVENUE BASE

Pre Ran!a"y A#$uisition Post Ran!a"y A#$uisition

2#$

1%$&$

%'$

2$

Sales(in s *illions)

S ene"ics ndian

ene"ics

#e"in

Ma"ets

0este"n

u"oe

A and

/t!e"s

US +eneri!s, -'$

.ndian +eneri!s, 22$

/0, 11$

P. /thers, 13$

Sales(in s *illions)

S ene"ics

ndian ene"ics

%/0

A /t!e"s

A* *,, ) /(, >+-( 60, /(, , /(/ S7-(+), :/,+ 897)+)>

R6; =* )/* */+> -+,*,8, ) ,>+-()8 -+,*,8, : S7-(+,/(,+ )* =, )0,+*):), ) /,+

7/23/2019 A1 Strategic Memo Final

8/13

.e!t-E$uity Ratio '.1! '.'1 '.'1 '.'1 '.'1 '.'1

ROE '."# !.5% 23.32 22.32 1!.54 2".'4

RO*E '.13 #.3 23.3% 23.2# 1".3% 2".3"

I/ )* 8,+ :+< /(, 60, :)>7+,* /(/ /(,+, ROE )* 6,, +,78)> +,* :+ /()* 6,)>

/(, :8/o T(, ,8))> -+:)/* : R6; (* ) /(, ROE S7-(+

7/23/2019 A1 Strategic Memo Final

9/13

SUN PHARMATACTICS AND STRATEGY

Figure 4: Ta!ti!s and Strategy

S7-(+(,+ 6+>))> -=,+ 6 7/))@)> ()>(,+ ,8

7/23/2019 A1 Strategic Memo Final

10/13

S7 CEO MD D))- S(>(0) ( =+, /(/ *6 (, *7+8)>

R/7 B(7+) )+,8/+:)8, /(,+*.

M*/ *,)+ ,(/ ) :/,+ J-,*, >)/D))8() 67>(/ R6; :+< /(, S)>( 6+/(,+* ) 2''#.T(, -+6,< :+ /(, *,)+ R6;,;,87/)0,* 6,8)@/) =)/( )/* =-,-,.

T(, )/,>+/) -+8,** : S7 P(+

7/23/2019 A1 Strategic Memo Final

11/13

ARENA

K E;)*/)4>D,0,3.-,1>,4,+)86+.21-+.178/ 3)4,

DIFFERENTIATOR

K L.= C.*/

K S/+.4>1)*/+)67/).44,/=.+?

K R,3)263,OTC

K S/+.4>*-,8)23/5-+.178/*

STAGINGAND PACING

K I,A :.2 2 :.4 3 :.6

#e"in Ma"ets :.3 4 1.2 4 1.2ene"ic "o*t!otential :.3 3 :.9 2 :.6

T75TS

8

7/23/2019 A1 Strategic Memo Final

12/13

ove"n#ent"eulations :.1 4 :.4 2 :.2"oduct =ia&ility;lai# :.1 1 :.1 2 :.2;o#etitive=andscae 1 3 2.8

Sum --- -4

I /()* 8*, )0,+*):)> /(, -+78/* ) ,= 87/+),* *8+,* ()>(,+ /( /(, /,+/, */+/,>

/(/ )* 5.55 5.3. S =, 8(*, /(, :)+*/ */+/,> 0,+ /(, /,+/, */+/,>.

TARNISHED BRAND IMAGE ISSUE OF RANBAXY

R6; L6+/+),* /(, I) >,,+)8 +7>

7/23/2019 A1 Strategic Memo Final

13/13

FUTURE STRATEGY& REMEDIAL ACTIONS

T(, (0, 8(,;-, RD /,+/) )* )),* ,*7+)> 6 -+8/)8, 8GMP

++/) 8(+>,* ) +,+ / >,,+/, >/,+< *,+>),*

:+< /(, ,+ =)/( R6;. E6+/)> /(, 8GMP 8 /,+